ΑΙhub.org
 

Accelerating drug development with AI


by
09 April 2025



share this:

This picture is made up of 9 images in rows of 3. Each row shows a different image of a pill bottle spilling out pills onto a plain surface, on yellow or white backgrounds. On one side, the image is an original photograph. The next two iterations show it getting represented in progressively larger blocks of colour.Rens Dimmendaal & Banjong Raksaphakdee / Medicines (flipped) / Licenced by CC-BY 4.0

Developing new drugs to treat illnesses has typically been a slow and expensive process. However, a team of researchers at the University of Waterloo uses machine learning to speed up the development time.

The Waterloo research team has created “Imagand,” a generative artificial intelligence model that assesses existing information about potential drugs and then suggests their potential properties. Trained on and tested against existing drug data, Imagand successfully predicts important properties of different drugs that have already been independently verified in lab studies, demonstrating the AI’s accuracy.

Traditionally, bringing a successful drug candidate to market can cost between US$2 billion and US$3 billion and take over a decade to complete. Generative AI is posed to transform drug discovery by harnessing large amounts of drug data across diverse areas.

The image from the study shows a correlation between pairs of pharmacokinetic (PK) properties for a single drug. Each drug has its unique chemical profile and set of PK property values. The goal of the diagram is to show the distribution similarity between the real reported pairs of PK properties correlation from in vitro studies and those generated by the researchers’ model. This is important to show that the tool can be helpful in guiding and reducing the cost of large in vitro assays and studies to accelerate pre-clinical drug discovery.

“There’s an enormous pool of possible chemicals and proteins to investigate when developing a new drug, which makes it very expensive to do drug discovery because you have to test millions of molecules with thousands of different targets,” said Bing Hu, a PhD candidate in Computer Science and the lead author on the research. “We are figuring out ways that AI can make that faster and cheaper.”

One of the major challenges in pharmaceutical medicine development is understanding not only how a drug might affect the body in isolation but also how it might interact with other drugs or a person’s lifestyle. This information is particularly difficult to gather because scientific studies of drugs usually only focus on the drugs’ predetermined properties, not on how they may interact with other drugs.

Ultimately, the team hopes medical researchers can use Imagand in the future to understand how drugs interact, allowing them to eliminate potential new drug candidates that would have bad side effects or interactions.

“For example, this AI-enabled process can help us understand how toxic a drug is, how it affects the heart, or how it might interact negatively with other drugs commonly used in treating an illness,” said Helen Chen, a professor in the School of Public Health Sciences and Computer Science at Waterloo. “This is one example of how AI is helping us move towards more precise, personalized care.”

The research, titled “Drug discovery SMILES-to-pharmacokinetics diffusion models with deep molecular understanding“, is currently in preprint.



tags: ,


University of Waterloo




            AIhub is supported by:


Related posts :



monthly digest

AIhub monthly digest: May 2025 – materials design, object state classification, and real-time monitoring for healthcare data

  30 May 2025
Welcome to our monthly digest, where you can catch up with AI research, events and news from the month past.

Congratulations to the #AAMAS2025 best paper, best demo, and distinguished dissertation award winners

  29 May 2025
Find out who won the awards presented at the International Conference on Autonomous Agents and Multiagent Systems last week.

The Good Robot podcast: Transhumanist fantasies with Alexander Thomas

  28 May 2025
In this episode, Eleanor talks to Alexander Thomas, a filmmaker and academic, about the transhumanist narrative.

Congratulations to the #ICRA2025 best paper award winners

  27 May 2025
The winners and finalists in the different categories have been announced.

#ICRA2025 social media round-up

  23 May 2025
Find out what the participants got up to at the International Conference on Robotics & Automation.

Interview with Gillian Hadfield: Normative infrastructure for AI alignment

  22 May 2025
Kumar Kshitij Patel spoke to Gillian Hadfield about her interdisciplinary research, career trajectory, path into AI alignment, law, and general thoughts on AI systems.

PitcherNet helps researchers throw strikes with AI analysis

  21 May 2025
Baltimore Orioles tasks Waterloo Engineering researchers to develop AI tech that can monitor pitchers using low-resolution video captured by smartphones

Interview with Filippos Gouidis: Object state classification

  20 May 2025
Read the latest interview in our series featuring the AAAI/SIGAI Doctoral Consortium participants.



 

AIhub is supported by:






©2025.05 - Association for the Understanding of Artificial Intelligence


 












©2025.05 - Association for the Understanding of Artificial Intelligence